Valuation: Xencor, Inc.

Market Cap 217.86Cr 186.68Cr 174.92Cr 159.78Cr 301.54Cr 21TCr 304.52Cr 2.06TCr 803.23Cr 10TCr 818Cr 800.18Cr 35TCr P/E 2026 *
-9.64x
P/E 2027 * -9.23x
Enterprise Value 174.56Cr 149.58Cr 140.16Cr 128.02Cr 241.61Cr 17TCr 243.99Cr 1.65TCr 643.59Cr 8.4TCr 655.42Cr 641.14Cr 28TCr EV / Sales 2026 *
12.1x
EV / Sales 2027 * 17.3x
Free-Float
98.78%
Yield 2026 *
-
Yield 2027 * -
1 day+1.05%
1 week+26.73%
Current month+44.98%
1 month+50.72%
3 months+159.06%
6 months+148.09%
Current year+91.38%
1 week 25.54
Extreme 25.545
30.61
1 month 19.04
Extreme 19.04
30.61
Current year 10.38
Extreme 10.375
30.61
1 year 7.71
Extreme 7.71
30.61
3 years 6.92
Extreme 6.92
30.61
5 years 6.92
Extreme 6.92
43.61
10 years 6.92
Extreme 6.92
58.34
Manager TitleAgeSince
Chief Executive Officer 55 01/02/2005
Director of Finance/CFO 48 09/04/2024
Chief Tech/Sci/R&D Officer 61 01/10/2006
Director TitleAgeSince
Director/Board Member 55 01/08/1997
Director/Board Member 58 25/07/2014
Director/Board Member 72 18/03/2015
Date Insider Type Main position Quantity % Market Cap.
16/06/26 Free

Director

30,906 0.0417%
23/01/26 Fiscal year

Chief Technology Officer

10,644 0.0149%
19/12/25 Fiscal year

Chief Technology Officer

2,32,723 0.3259%
Change 5-day change 1-year change 3-year change Capi.($)
+1.05%+26.73%+248.39%+29.70% 215.59Cr
+3.31%-3.53%+71.28%+104.57% 6.91TCr
+1.74%+2.81%+55.45%+88.75% 6.31TCr
+1.09%+24.51%+2.86%-4.20% 2.83TCr
-0.07%-3.45%-6.06%+464.93% 2.71TCr
+7.41%+13.08%+58.57%+17.04% 2.55TCr
+3.98%+4.37%+39.87%-15.08% 1.97TCr
+1.02%+5.67%+273.94%+420.34% 1.92TCr
+0.10%+0.19%+12.19%+550.31% 1.6TCr
+3.98%+8.41%+46.83%+160.78% 1.35TCr
Average +2.36%+6.09%+80.33%+181.72% 2.83TCr
Weighted average by Cap. +2.51%+3.12%+60.78%+157.00%

Financials

2026 *2027 *
Net sales 14Cr 12Cr 12Cr 11Cr 20Cr 1.37TCr 20Cr 136.3Cr 53Cr 692.21Cr 54Cr 53Cr 2.29TCr 13Cr 11Cr 10Cr 9.21Cr 17Cr 1.2TCr 18Cr 118.97Cr 46Cr 604.19Cr 47Cr 46Cr 2TCr
Net income -24Cr -20Cr -19Cr -17Cr -33Cr -2.27TCr -33Cr -225.81Cr -88Cr -1.15TCr -90Cr -88Cr -3.8TCr -28Cr -24Cr -22Cr -21Cr -39Cr -2.66TCr -39Cr -264.75Cr -103.06Cr -1.34TCr -104.96Cr -102.67Cr -4.45TCr
Net Debt -43Cr -37Cr -35Cr -32Cr -60Cr -4.13TCr -61Cr -410.1Cr -159.65Cr -2.08TCr -162.58Cr -159.04Cr -6.9TCr -
Logo Xencor, Inc.
Xencor, Inc. is a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases. It has more than 20 candidates engineered with its XmAb technology that are in clinical development, and multiple XmAb medicines are marketed by partners. Its XmAb engineering technology enables small changes to a protein structure that result in new mechanisms of therapeutic action. Its wholly-owned development candidates include XmAb942, XmAb819, XmAb808, and XmAb541. Candidates co-developed with partners include Plamotamab. Its clinical-stage drug candidates advanced by partners include Xaluritamig (AMG 509), ASP2138, JNJ-9401, JNJ-1493, Xpro1595, Obexelimab, and Novartis XmAb, an undisclosed antibody candidate. Its cytokine drug candidates in clinical development consist of efbalropendekin alfa (XmAb306/RG6323). Its Vudalimab is a bispecific antibody that targets PD-1 and CTLA-4.
Employees
260
Date Price Change Volume
25/26/25 $29.30 +1.05% 15,62,660
24/26/24 $29.00 +4.30% 10,50,750
21/26/21 $27.80 +2.96% 7,53,106
20/26/20 $27.00 -1.89% 16,55,225
19/26/19 $27.52 +8.30% 23,51,122
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
14
Last Close Price
29.30USD
Average target price
29.00USD
Spread / Average Target
-1.02%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. XNCR Stock